Seropositive rheumatoid arthritis (RA) is RA where a blood test finds antibodies, either rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). A 2017 review says this group makes up about two-thirds of RA cases and generally has a more severe disease course. The choice of treatment for you is still a conversation with a rheumatology clinician.
What is rheumatoid arthritis (RA)?
The NIAMS rheumatoid arthritis page says RA is “a chronic (long-lasting) autoimmune disease that mostly affects joints.” In plain terms, your immune system, which normally fights infection, attacks the lining of your joints. As of October 2026, that page says the disease causes pain, swelling, stiffness and loss of function, and that it often affects the same joints on both sides of the body.
The common signs are joint pain at rest and when you move, stiffness that lasts longer than 30 minutes (usually after waking), and swelling that makes it hard to make a fist, comb your hair or button clothes. You may also feel unusually tired, have a low-grade fever or lose your appetite. RA can also affect the heart, lungs, blood, nerves, eyes and skin.
About two to three times as many women as men have the disease, according to the same NIAMS page.
Seropositive vs seronegative: what the difference means
Doctors sort RA by blood antibodies. Seropositive RA has RF or ACPA. Seronegative RA has neither. A recent review describes seronegative RA as “defined by the absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA)” and says it “represents 20-30% of rheumatoid arthritis cases” (recent seronegative RA review).
Why the label matters for your outlook
The 2017 review in Nature Reviews Immunology (2017 Nature Reviews Immunology review) notes that RF and ACPA are often in the blood long before joint inflammation shows up. The 2024 literature review in Cells (2024 Cells review) says that over the last two decades, long-term outcomes have improved significantly in seropositive RA but not in seronegative RA. That same review says about 40% of patients with RA do not respond to individual drugs, and up to 20% do not respond to any of the available medications.
What older research found
An older study of 140 randomly selected patients from Alabama (older Alabama study) found subcutaneous nodules (firm lumps under the skin) at 37.5% and vasculitis (inflamed blood vessels) at 6.3% only in seropositive RA. In that study, the gene marker DR4 was linked with more destructive disease in the seronegative group. The authors concluded that seronegative RA is “a disease entity clinically and immunogenetically distinct from seropositive RA.”
Why a diagnosis can take time
The seronegative review includes a diagnostic chart listing other conditions to consider, such as osteoarthritis, psoriatic arthritis and systemic lupus erythematosus. A 2021 scoping review of the research (2021 periodontal disease review) found mixed results on whether gum disease differs between antibody-positive and antibody-negative RA.
What are the treatment options for seropositive RA?
The NIAMS page says the goal of treatment “is to control the disease so it is in remission or near remission, with no signs or symptoms of the disease.” The table below lists the main options and what each one is and is not known for, so you can compare them side by side and bring the table to your clinician.
| Option | Status | What the evidence shows | Who it may suit | Cost and limits |
|---|---|---|---|---|
| Conventional synthetic DMARDs (for example methotrexate, hydroxychloroquine, sulfasalazine, leflunomide) | Prescription drug therapy | These drug groups come from a proposed treatment chart for seronegative RA in the seronegative review, which also says cytokine and JAK inhibitors work largely regardless of serostatus. NIAMS says “current treatments can help people with the disease to lead productive lives.” | Chosen by your clinician from your test results and history | Costs vary; check with your pharmacy and plan. About 40% of patients do not respond to individual drugs (2024 Cells review). |
| Biologic and targeted synthetic DMARDs (for example TNF, IL-6 receptor and JAK targets) | Prescription drug therapy | Appears in the same seronegative RA treatment chart as the drugs above. | Chosen by your clinician | Costs vary; check with your pharmacy and plan. Ask your clinician about the risks and what monitoring is planned. |
| Glucocorticoids (steroids) | Prescription drug therapy | Appears in the same seronegative RA treatment chart. | Chosen by your clinician | Costs vary. Your clinician decides how long and how much. |
| Balneotherapy (bathing in mineral water, or mud packs) | Non-drug option | NCCIH says “there’s evidence that balneotherapy may be helpful for improving quality of life in people with rheumatoid arthritis.” | People who want a non-drug option for quality of life | Costs vary; check locally. The benefit described is quality of life, not joint damage. |
| Omega-3 fatty acids (fish oil) | Supplement | NCCIH says they “may have beneficial effects on rheumatoid arthritis when used in addition to conventional drug therapy.” | People discussing it alongside their medicines | Price varies by product. Supplements can interact with medicines. |
| Gamma-linolenic acid (evening primrose, borage seed and black currant seed oils) | Supplement | NCCIH describes “preliminary evidence.” | People discussing it with a clinician | Price varies by product. The evidence is preliminary. |
| Thunder god vine | Herb | NCCIH describes “preliminary evidence” for a few supplements, including this herb. | People discussing it with a clinician | Price varies by product. The evidence is preliminary. |
| Tai chi | Movement practice | A few small studies have tested it in RA. NCCIH says “it’s uncertain whether this approach is helpful.” | People who want gentle movement with a qualified teacher | Class costs vary. NCCIH notes it can cause sore muscles and some risk of injury. |
According to NCCIH, no nutritional approach other than omega-3 fatty acids has shown clear benefits for RA. Treat the rest of the list as possible additions to care, not substitutes for it.
Can I treat rheumatoid arthritis myself?
You can take steps on your own to support your daily life, and some of them are backed by research. The NIAMS page lists smoking and obesity as factors linked to RA. It says that for people who continue to smoke, the disease may be more severe, and that obesity may limit how much the disease can be improved.
Two cautions matter most. First, NCCIH says “‘Natural’ doesn’t always mean ‘safe.’ Some dietary supplements may have side effects and may interact with medications.” It also says the U.S. Food and Drug Administration has warned about dietary supplements promoted for arthritis or pain that were tainted with prescription drugs (NCCIH chronic pain fact sheet). Second, NIAMS says flares can be triggered by stress, cigarette smoke, viral infections, too much activity or suddenly stopping medications. Do not change any medicine on your own. Ask your clinician first.
If you are considering or using a complementary approach for pain, NCCIH says to “check with your health care providers to make sure it’s safe for you.” Bring any supplement label to that conversation. To track flares, the guide on a pain flare that is different from your usual pattern can help you decide what to report.
What is living with rheumatoid arthritis like?
RA affects people differently. The NIAMS page says that in some people it starts with mild or moderate inflammation in just a few joints. If it is not treated or treatments are not working, it can worsen and affect more joints.
The NIAMS page also gives a more hopeful picture: “Fortunately, current treatments can help people with the disease to lead productive lives.” Your own path depends on your results, your joints and your treatment plan, so keep a simple record of stiffness, flares and daily tasks to bring to each visit.
Is there a charity, and what about benefits or disability pay?
To find patient groups near you, ask your rheumatology clinic, which can often point you to local support. For benefits such as PIP or disability pay, ask the clinic’s staff or a local benefits adviser which agency handles claims in your area and what paperwork it needs.
If you have heard about traditional approaches from other countries, bring them to your clinician. Your clinician can tell you what is known about each one for your situation.
Before you decide: questions and wording for your clinician
- Is my RA seropositive or seronegative, and what were my RF and ACPA results?
- Could a clinical trial be an option for me?
- Which drug group fits my results, and what would we check along the way?
- Which supplements am I taking, and could any interact with my medicines? Bring every label.
- Which changes in my joints or energy should I report between visits?
Wording to use at the visit: “I have been told I have rheumatoid arthritis. I want to know whether my antibody results make it seropositive or seronegative, and what that means for my treatment choices.”
Before the visit, prepare your list with your medication list for a pain-care visit. If a plan needs to change, when a pain-care plan changes lists the follow-up questions to ask. For a plain-language overview of pain care, see understanding pain care.
For the full background on RA, see the MedlinePlus rheumatoid arthritis page.
By the Pain Care Questions Team
Leave a Reply